Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 13 | 2011 | 18 | 1.940 |
Why?
|
| Nuclear Proteins | 7 | 2002 | 23 | 1.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2024 | 11 | 0.960 |
Why?
|
| Piperazines | 2 | 2017 | 6 | 0.860 |
Why?
|
| Imidazoles | 2 | 2017 | 17 | 0.860 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2001 | 9 | 0.860 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 2 | 0.840 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 4 | 0.840 |
Why?
|
| Ubiquitins | 6 | 2001 | 7 | 0.660 |
Why?
|
| Osteosarcoma | 2 | 2017 | 7 | 0.610 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 14 | 0.600 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 7 | 2011 | 7 | 0.560 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 4 | 0.520 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 10 | 0.520 |
Why?
|
| Humans | 16 | 2024 | 2957 | 0.470 |
Why?
|
| Cell Nucleus | 4 | 2002 | 9 | 0.430 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 23 | 0.430 |
Why?
|
| Mutation | 3 | 2011 | 77 | 0.420 |
Why?
|
| Ultraviolet Rays | 4 | 2001 | 7 | 0.360 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2008 | 6 | 0.340 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 16 | 0.340 |
Why?
|
| Zinc Fingers | 2 | 2000 | 2 | 0.310 |
Why?
|
| Mitosis | 1 | 2008 | 1 | 0.280 |
Why?
|
| Benzoquinones | 1 | 2008 | 1 | 0.280 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 1 | 0.280 |
Why?
|
| Lactams, Macrocyclic | 1 | 2008 | 1 | 0.280 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2008 | 1 | 0.280 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 3 | 0.280 |
Why?
|
| Tumor Cells, Cultured | 8 | 2001 | 17 | 0.230 |
Why?
|
| Transfection | 5 | 2001 | 19 | 0.220 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2001 | 2 | 0.220 |
Why?
|
| Apoptosis | 2 | 2017 | 36 | 0.220 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2024 | 2 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2024 | 8 | 0.210 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 8 | 0.210 |
Why?
|
| Interleukin-6 | 1 | 2024 | 21 | 0.210 |
Why?
|
| G1 Phase | 2 | 2000 | 4 | 0.190 |
Why?
|
| Down-Regulation | 2 | 2001 | 22 | 0.180 |
Why?
|
| Ubiquitin | 1 | 2001 | 3 | 0.180 |
Why?
|
| Signal Transduction | 1 | 2002 | 97 | 0.170 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 69 | 0.170 |
Why?
|
| Protein Binding | 3 | 2011 | 25 | 0.170 |
Why?
|
| Alkylating Agents | 1 | 2001 | 1 | 0.170 |
Why?
|
| Cyclins | 2 | 1997 | 3 | 0.160 |
Why?
|
| Female | 1 | 2024 | 1724 | 0.150 |
Why?
|
| Cell Line | 4 | 2002 | 56 | 0.140 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 6 | 0.130 |
Why?
|
| Pyrazines | 1 | 2017 | 5 | 0.130 |
Why?
|
| Drug Synergism | 1 | 2017 | 9 | 0.130 |
Why?
|
| Cisplatin | 1 | 2017 | 5 | 0.130 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2017 | 9 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 6 | 0.130 |
Why?
|
| Animals | 6 | 2002 | 1050 | 0.130 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1997 | 1 | 0.130 |
Why?
|
| Gamma Rays | 1 | 1997 | 4 | 0.130 |
Why?
|
| DNA Damage | 3 | 2001 | 3 | 0.130 |
Why?
|
| Cysteine Endopeptidases | 1 | 1996 | 1 | 0.120 |
Why?
|
| Multienzyme Complexes | 1 | 1996 | 12 | 0.120 |
Why?
|
| RNA, Messenger | 4 | 2001 | 59 | 0.110 |
Why?
|
| DNA | 3 | 2001 | 28 | 0.100 |
Why?
|
| Ribosomal Proteins | 2 | 1990 | 2 | 0.100 |
Why?
|
| Clone Cells | 1 | 2011 | 4 | 0.090 |
Why?
|
| Cytoplasm | 2 | 2001 | 11 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 2 | 2001 | 6 | 0.080 |
Why?
|
| Drosophila | 1 | 1990 | 1 | 0.080 |
Why?
|
| G2 Phase | 1 | 2008 | 1 | 0.070 |
Why?
|
| HT29 Cells | 1 | 2008 | 1 | 0.070 |
Why?
|
| HCT116 Cells | 1 | 2008 | 2 | 0.070 |
Why?
|
| Cell Division | 1 | 2008 | 9 | 0.070 |
Why?
|
| Base Sequence | 4 | 2002 | 24 | 0.070 |
Why?
|
| Genes, p53 | 2 | 2001 | 2 | 0.050 |
Why?
|
| Tumor Protein p73 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 1 | 0.050 |
Why?
|
| Chickens | 1 | 2002 | 4 | 0.050 |
Why?
|
| DNA Primers | 1 | 2002 | 12 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2002 | 6 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2001 | 2 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 2001 | 2 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2001 | 5 | 0.040 |
Why?
|
| Plasmids | 1 | 2001 | 10 | 0.040 |
Why?
|
| Epitopes | 1 | 2001 | 6 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2001 | 21 | 0.040 |
Why?
|
| Methyl Methanesulfonate | 1 | 2001 | 1 | 0.040 |
Why?
|
| Phosphoserine | 1 | 2001 | 1 | 0.040 |
Why?
|
| Mitomycin | 1 | 2001 | 1 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2001 | 28 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2001 | 17 | 0.040 |
Why?
|
| Salmon | 1 | 2000 | 1 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2000 | 4 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2001 | 119 | 0.040 |
Why?
|
| DNA Repair | 1 | 2000 | 1 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 6 | 0.040 |
Why?
|
| Ligases | 1 | 1999 | 1 | 0.040 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1999 | 1 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 1999 | 5 | 0.040 |
Why?
|
| Oxygen | 1 | 1999 | 9 | 0.040 |
Why?
|
| Time Factors | 1 | 2000 | 208 | 0.040 |
Why?
|
| Protein Conformation | 1 | 1999 | 22 | 0.040 |
Why?
|
| Point Mutation | 1 | 1999 | 12 | 0.040 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1997 | 2 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1997 | 4 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 47 | 0.030 |
Why?
|
| Leupeptins | 1 | 1996 | 1 | 0.030 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1996 | 1 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 1996 | 1 | 0.030 |
Why?
|
| Acetylcysteine | 1 | 1996 | 3 | 0.030 |
Why?
|
| Gene Expression | 1 | 1996 | 45 | 0.030 |
Why?
|
| Male | 1 | 2000 | 1860 | 0.030 |
Why?
|
| Neoplasms | 1 | 1995 | 18 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1990 | 1 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1990 | 11 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 1990 | 7 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 31 | 0.010 |
Why?
|
| DNA Probes | 1 | 2001 | 2 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 4 | 0.010 |
Why?
|
| Introns | 1 | 2001 | 6 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 12 | 0.010 |
Why?
|
| Cattle | 1 | 2001 | 17 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2001 | 72 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2001 | 16 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1999 | 1 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 1999 | 1 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 1999 | 5 | 0.010 |
Why?
|
| Proteins | 1 | 1999 | 9 | 0.010 |
Why?
|
| Mice | 1 | 2001 | 343 | 0.010 |
Why?
|
| Autoradiography | 1 | 1995 | 1 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 1995 | 1 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1995 | 3 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1995 | 23 | 0.010 |
Why?
|
| Cell Survival | 1 | 1995 | 19 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1995 | 23 | 0.010 |
Why?
|
| Xenopus laevis | 1 | 1990 | 1 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1990 | 1 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 2 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1990 | 6 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1990 | 31 | 0.010 |
Why?
|